Cue Biopharma Inc. Common Stock (CUE)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have always looked for businesses that earn consistent profits, generate cash, and possess durable competitive advantages. Cue Biopharma fails those tests today. It is a clinical-stage biotech with 29 employees, a Phase 2 asset, and no proven commercial product. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $7.9M and net income was -$153.1M, or diluted EPS -$24.14. That large loss followed fiscal Q1 2026, the quarter ended 2026-03-31, when net income was -$5.2M on revenue of $5.7M. For fiscal year 2025, the year ended 2025-12-31, revenue was $27.5M and net income was -$26.6M, or diluted EPS -$0.28. In fiscal year 2024, the year ended 2024-12-31, revenue was $9.3M and net income was -$40.7M. In fiscal year 2023, the year ended 2023-12-31, revenue was $5.5M and net income was -$50.7M. So revenue has grown from a tiny base, but losses persist. FairStock's calculations show a price-to-book of 44.48 at the 2026-10-13 close, ROE of -1603.48%, ROCE of -172.66%, and a Piotroski F-Score of 3/9. Trailing free cash flow is -$50.2M, an FCF yield of -88.0% on a $57.0M market cap. The Altman Z-Score is -31.77, and debt-to-equity is 1.33. With a 2.46 beta and a 52-week range of $4.98 to $45.50, the stock is speculative. By FairStock's Lynch rules, no category fits because it lost money in each of the last four years. There is no margin of safety in the Graham sense: no earnings, negative cash flow, and a high price relative to book value. The company's future depends on clinical and financing events, not on present business quality.

In plain English: Cue Biopharma is a small clinical-stage biotech trying to develop immune-system medicines. The business looks weak today: it has very little revenue, big losses, and spends more cash than it brings in. At the 2026-10-13 close of $19.57, the price looks expensive compared with its current profits and accounting value, so investors are paying mostly for future drug hope, not today's numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer